Tocotrienol SupraBio

`Tocotrienol SupraBio` is a patented self-emulsifying drug delivery system (SEDDS) formulation of mixed tocotrienols (isomers of vitamin E) developed by Hovid. The formulation is designed to enhance the oral absorption and bioavailability of tocotrienols by up to 300%, allowing them to reach therapeutic concentrations in vital organs such as the brain and liver. It consists of a natural mixture of alpha-, gamma-, and delta-tocotrienols along with alpha-tocopherol, plant squalene, phytosterols, and phytocarotenoids extracted from palm oil. `Tocotrienol SupraBio` is being clinically evaluated in Phase 2 trials for several indications, including Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL), end-stage liver disease, nonalcoholic fatty liver disease (NAFLD), diabetic peripheral neuropathy, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). It has received US FDA Orphan Drug designation for CADASIL.

Brand names

Tocovid PromemoTocovid SupraBioTocovid SupraBio Promemo

Other names

EVNol SupraBiomixed tocotrienolspalm tocotrienols complexPalm Vitamin ETocotrienol SupraBio systemTocotrienol SupraBio™ system